| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may be a carbonic anhydrase inhibitor although this is not one of the primary mechanisms of action. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels leading to a reduction of T-type calcium channel currents, or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory neurotransmitter GABA while enhancing the uptake of the excitatory neurotransmitter glutamate. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Murata M, Horiuchi E, Kanazawa I: Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res. 2001 Dec;41(4):397-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11755227 # Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR: Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 Apr 9;289(14):1820-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12684361 # Hasegawa H: Utilization of zonisamide in patients with chronic pain or epilepsy refractory to other treatments: a retrospective, open label, uncontrolled study in a VA hospital. Curr Med Res Opin. 2004 May;20(5):577-80. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15140322 # Leppik IE: Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure. 2004 Dec;13 Suppl 1:S5-9; discussion S10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15511691 # Ueda Y, Doi T, Tokumaru J, Willmore LJ: Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):1-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12941455 # Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders. Mini Rev Med Chem. 2008 Sep;8(10):968-75. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18782051 # Schulze-Bonhage A: Zonisamide in the treatment of epilepsy. Expert Opin Pharmacother. 2010 Jan;11(1):115-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/20001433 # Kothare SV, Kaleyias J: Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol. 2008 Apr;4(4):493-506. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18433351 # Peters DH, Sorkin EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs. 1993 May;45(5):760-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/7686468 # Sobieszek G, Borowicz KK, Kimber-Trojnar Z, Malek R, Piskorska B, Czuczwar SJ: Zonisamide: a new antiepileptic drug. Pol J Pharmacol. 2003 Sep-Oct;55(5):683-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14704463 (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - For use as adjunctive treatment of partial seizures in adults with epilepsy. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Zonisamide binds to sodium channels and voltage sensitive calcium channels, which suppresses neuronal depolarization and hypersynchronization. Zonisamide also inhibits carbonic anhydrase to a weaker extent, but such an effect is not thought to contribute substantially to the drug's anticonvulsant activity. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...outeOfElimination
| - Zonisamide is excreted primarily in urine as parent drug and as the glucuronide of a metabolite. (en)
|
| http://linked.open.../drugbank/synonym
| - 1,2-Benzisoxazole-3-methanesulfonamide (en)
- 3-(Sulfamoylmethyl)-1,2-benzisoxazole (en)
- Benzo[D]isoxazol-3-yl-methanesulfonamide (en)
- Zonisamida (en)
- Zonisamidum (en)
|
| http://linked.open...drugbank/toxicity
| - Symptoms of overdose include diminished breathing, loss of consciousness, low blood pressure, and slow heartbeat. (en)
|
| http://linked.open...umeOfDistribution
| |
| http://linked.open...nk/proteinBinding
| - 40% (at concentrations of 1.0-7.0 µg/mL) (en)
|
| http://linked.open...ynthesisReference
| - Tamar Nidam, "Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms." U.S. Patent US20030114682, issued June 19, 2003. (en)
|
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...logy/drugbank/pKa
| |
| http://linked.open...l/drug/hasATCCode
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)